Regent Assay advises Covalon on its acquisition of AquaGuard

Press Release

01 October 2018

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV.V; OTCQX: CVALF), an advanced medical technologies company, specialising in woundcare, today announced that it has closed the acquisition (the “Closing”) of AquaGuard, the Seattle, Washington-based division of medical technologies company Cenorin, LLC. AquaGuard’s specialized products provide patients with crucial moisture protection for wound, surgical, and vascular access sites throughout the body while showering.

Covalon were advised on the buyside by Canadian firm Morrison Park with Ian Bussey of Regent Assay providing support on the transaction in London. Ian is a leading authority on M&A activities in the Medical Devices field and supported Covalon with their global search, approach and valuation of Aquaguard.